Enanta Pharmaceuticals Inc. has discovered mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, ...

The kinase inhibitor imatinib has been highly successful ... focusing its specificity on C-Kit (also known as KIT) kinase inhibition (the therapeutic target for GIST) while reducing its effect ...

while the biotech also has a c-KIT inhibitor called SLRN-517 in preclinical development, which it says has potential to treat chronic urticaria. Acelyrin has already secured more than $550 million ...

The company announced results for a phase 1 trial of various doses of the KIT inhibitor, dubbed THB335, in healthy volunteers this morning. Dose-dependent reductions in serum tryptase, a biomarker ...